| Dermatitis, Atopic
Cibinqo vs Rayos
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Cibinqo vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Cibinqo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Cibinqo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cibinqo
Rayos
At A Glance
Oral
Once daily
JAK inhibitor
Oral
Daily
Corticosteroid
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Dermatitis, Atopic 100 mg orally once daily; may increase to 200 mg once daily for inadequate response. In moderate renal impairment or CYP2C19 poor metabolizers: 50 mg once daily, may increase to 100 mg once daily for inadequate response.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- Patients taking antiplatelet therapies (except low-dose aspirin <=81 mg daily) during the first 3 months of treatment
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=1%) Nasopharyngitis (8.7-12.4%), nausea (6.0-14.5%), headache (6.0-7.8%), herpes simplex (3.3-4.2%), increased blood creatine phosphokinase (2.3-2.9%), dizziness (1.8-2.9%), urinary tract infection (1.7-2.2%), fatigue (1.3-1.6%), acne (1.6-4.7%), vomiting (1.5-3.2%), impetigo (0.5-1.5%), oropharyngeal pain (1.0-1.4%), hypertension (0.8-1.2%), influenza (1.1-1.2%), gastroenteritis (1.1-1.3%), dermatitis contact (0.5-1.1%), abdominal pain upper (0.6-1.9%), abdominal discomfort (0.5-1.2%), herpes zoster (0.3-1.2%), thrombocytopenia (0-1.5%)
Serious Serious infections including herpes simplex, herpes zoster, and pneumonia (2.3 per 100 patient-years); thrombosis including pulmonary embolism and deep vein thrombosis; major adverse cardiovascular events; malignancy; retinal detachment
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Abrocitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits JAK1 by blocking the ATP binding site. It is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and TYK2 (43-fold).
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cibinqo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Cibinqo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cibinqo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CibinqoView full Cibinqo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.